Can HDAC inhibitors to prevent the development of drug resistance in melanoma?

Moffitt Cancer Center researchers have discovered a mechanism by which melanoma cells become resistant to drugs that target the BRAF protein and its signaling pathway.

Their study was published online in the journal Cancer Research.

Mutations in BRAF are found in approximately 50 percent of all melanomas, leading to increased cell proliferation and survival. Several drugs are available that target BRAF and a downstream gene named MEK that cooperates with BRAF in cancer development. These drugs have resulted in significant improvements in patient outcomes; however, many patients eventually develop drug resistance.

In a series of laboratory experiments with cell lines and mouse models, researchers discovered that melanoma cells that are resistant to BRAF inhibitors undergo a similar response mechanism as cells treated with stress-inducing factors, such as UV radiation and low oxygen. During each of these conditions, the cells increased expression of the protein histone deacetylase 8 (HDAC8).

HDACs are proteins that regulate the expression level and activity of other proteins within the cell. HDACs are often deregulated in cancer and several drugs that target HDACs are approved for the treatment of different types of cancer. The researchers found that HDAC8 stimulated the activity of the AP-1 transcription factor that subsequently increased the expression of genes that are involved in cell motility and invasion.

"Our work provides the first evidence that HDAC8 activity is increased in responses to multiple, diverse cellular stresses, and that this in turn initiates a transcriptional program that is associated with increased melanoma cell survival," explains Keiran Smalley, PhD, director of the Donald A. Adams Melanoma and Skin Cancer Center of Excellence at Moffitt, in a news release.

This link between HDAC8 and drug resistance suggested to the researchers that drugs targeting HDACs may be able to overcome cellular resistance mechanisms to BRAF inhibitors. The researchers performed a series of mouse experiments and found that co-treatment with both HDAC and BRAF inhibitors inhibited melanoma tumor growth better than either agent alone.

The researchers hope their work will lead to clinical studies that will examine the potential of HDAC inhibitors to prevent the development of drug resistance in melanoma. "These findings provide a strong rationale to pursue the development of more selective and potent HDAC8 inhibitors for future evaluation as drugs that can limit phenotype switching and therapeutic escape in melanoma," says Smalley.